All In Biotech

Drug Trial Radar · NCT06346392

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

594

Actual

Start

Mar 4, 2024

Primary completion

May 31, 2026

Study completion Oct 14, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Interventions

  • AZD0901Drug

    Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV

  • AZD0901Drug

    Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)

  • Ramucirumab+ paclitaxelDrug

    Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W

  • PaclitaxelDrug

    Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)

  • DocetaxelDrug

    Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)

  • IrinotecanDrug

    Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W

  • TAS-102Drug

    TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)

  • ApatinibDrug

    Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) in all randomized participantsTime frame: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).
  2. Overall Survival (OS) for 3L+ participantsTime frame: From date of first dose/randomisation until the date of death due to any cause (approximately 3 years).

Locations

158 sites in 19 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Duarte, California

  • Research Site

    Irvine, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Hollywood, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Marietta, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Lexington, Kentucky

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Kansas City, Missouri

  • Research Site

    Mineola, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    York, Pennsylvania

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Fredericksburg, Virginia

  • Research Site

    Olympia, Washington

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Vitória, Brazil

  • Research Site

    Barrie, Ontario, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    North York, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Fuzhou, China

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.